198 related articles for article (PubMed ID: 22151386)
1. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Kuschal C; Thoms KM; Schubert S; Schäfer A; Boeckmann L; Schön MP; Emmert S
Exp Dermatol; 2012 Jan; 21(1):2-6. PubMed ID: 22151386
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Thoms KM; Kuschal C; Oetjen E; Mori T; Kobayashi N; Laspe P; Boeckmann L; Schön MP; Emmert S
Exp Dermatol; 2011 Mar; 20(3):232-6. PubMed ID: 21323745
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
5. [Swiss clinical practice guidelines for skin cancer in organ transplant recipients].
Lapointe AK; Hofbauer G; Anliker M; Arnold A; Binet I; Hunger R; Kempf W; Pascual M; Pelloni F; Serra A; Laffitte E
Rev Med Suisse; 2010 Apr; 6(246):854-9. PubMed ID: 20455382
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive drugs and the development of skin cancer after organ transplantation].
Gjersvik P; Helsing P; Holdaas H; Bergan S
Tidsskr Nor Laegeforen; 2012 Oct; 132(18):2064-8. PubMed ID: 23038197
[TBL] [Abstract][Full Text] [Related]
7. The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients.
Durando B; Reichel J
Dermatol Ther; 2005; 18(1):1-11. PubMed ID: 15842607
[TBL] [Abstract][Full Text] [Related]
8. Organ transplantation and skin cancer: basic problems and new perspectives.
Hofbauer GF; Bouwes Bavinck JN; Euvrard S
Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
[TBL] [Abstract][Full Text] [Related]
10. Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition.
de Boer J; van Steeg H; Berg RJ; Garssen J; de Wit J; van Oostrum CT; Beems RB; van der Horst GT; van Kreijl CF; de Gruijl FR; Bootsma D; Hoeijmakers JH; Weeda G
Cancer Res; 1999 Jul; 59(14):3489-94. PubMed ID: 10416615
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
[TBL] [Abstract][Full Text] [Related]
12. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants.
Otley CC; Coldiron BM; Stasko T; Goldman GD
Arch Dermatol; 2001 Apr; 137(4):459-63. PubMed ID: 11295926
[TBL] [Abstract][Full Text] [Related]
13. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
Euvrard S; Ulrich C; Lefrancois N
Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847
[TBL] [Abstract][Full Text] [Related]
16. Future trends in organ transplant recipients--important issues for dermatologists.
Zecher D; Steiger J
Curr Probl Dermatol; 2012; 43():71-80. PubMed ID: 22377921
[TBL] [Abstract][Full Text] [Related]
17. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
18. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
19. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
Jung JW; Overgaard NH; Burke MT; Isbel N; Frazer IH; Simpson F; Wells JW
Int J Cancer; 2016 Jan; 138(2):281-92. PubMed ID: 25612559
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive drugs in organ transplant recipients--rationale for critical selection.
Stucker F; Marti HP; Hunger RE
Curr Probl Dermatol; 2012; 43():36-48. PubMed ID: 22377918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
